Literature DB >> 7633012

Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists.

J A Generali1, M A Danish, S E Rosenbaum.   

Abstract

OBJECTIVE: To survey pharmacists' knowledge of the adverse drug reaction (ADR) reporting process, as well as the nature and seriousness of ADRs observed by pharmacists, and to determine how pharmacists perceive their role in monitoring and reporting suspected reactions.
DESIGN: A survey was mailed to 793 Rhode Island pharmacists with a 40% (318) response rate.
RESULTS: Two hundred and thirty-five surveys were reviewed for final analysis. Pharmacists in retail settings were more likely than hospital pharmacists to be aware of ADRs relating to therapeutic inequivalence and over-the-counter products, and more likely to ask the patient about ADRs (40% vs 16%). Hospital pharmacists were more likely to receive ADR information from physicians (40% vs 15%). Almost all pharmacists (97%) believed that action should be taken when a serious ADR is suspected. Younger pharmacists (< 45 y) were more willing to contact the physician and refer the patient to medical attention.
CONCLUSIONS: Our results show that fewer than half of the respondents (41%) claimed to have observed a serious ADR (potentially life-threatening or requiring hospitalization), although almost all (97%) believed that pharmacists should take some action when a serious ADR is suspected. The influence of the practice setting, the number of years in practice, and the number of hours worked per week influenced the reporting practices and attitudes.

Entities:  

Mesh:

Year:  1995        PMID: 7633012     DOI: 10.1177/106002809502900404

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  23 in total

1.  Reporting of adverse drug reactions by poison control centres in the US.

Authors:  P A Chyka; S W McCommon
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

2.  Stimulating spontaneous reporting of adverse drug reactions by a patient : directed incentive.

Authors:  Slobodan Jankovic
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Texas pharmacists' opinions on reporting serious adverse drug events to the Food and Drug Administration: a qualitative study.

Authors:  Paul Gavaza; Carolyn M Brown; Star Khoza
Journal:  Pharm World Sci       Date:  2010-07-23

4.  Influence of pharmacists' attitudes on adverse drug reaction reporting : a case-control study in Portugal.

Authors:  Maria T Herdeiro; Adolfo Figueiras; Jorge Polónia; J J Gestal-Otero
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region.

Authors:  Marta Irujo; Guadalupe Beitia; Maira Bes-Rastrollo; Adolfo Figueiras; Sonia Hernández-Díaz; Berta Lasheras
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  The knowledge and attitude of the Turkish community pharmacists toward pharmacovigilance in the Kadikoy district of Istanbul.

Authors:  Hale Zerrin Toklu; Meral Keyer Uysal
Journal:  Pharm World Sci       Date:  2008-03-19

Review 7.  Determinants of under-reporting of adverse drug reactions: a systematic review.

Authors:  Elena Lopez-Gonzalez; Maria T Herdeiro; Adolfo Figueiras
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

8.  Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran.

Authors:  Ghazal Vessal; Zeinab Mardani; Mehri Mollai
Journal:  Pharm World Sci       Date:  2008-12-31

9.  Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal.

Authors:  Maria T Herdeiro; Jorge Polónia; Juan J Gestal-Otero; Adolfo Figueiras
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

10.  Influence of attitudes on pharmacists' intention to report serious adverse drug events to the Food and Drug Administration.

Authors:  Paul Gavaza; Carolyn M Brown; Kenneth A Lawson; Karen L Rascati; James P Wilson; Mary Steinhardt
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.